Riskpilot← Back to searchSign inGet full accessIconovo AB
ABActiveOrg 5569380156Ideongatan 3 BResearch and experimental development on natural sciences and engineering · NACE 7210Est. 201310-19 employees
Revenue 2024
SEK 2,9M
-59% vs 2023
EBITDA margin
-1157.9%
+8% vs 2023
Equity ratio
94.0%
Financial strength
Net profit 2024
SEK -40,9M
+7% vs 2023
| Revenue | SEK 2,9M | -59% |
| EBITDA | SEK -34M | +8% |
| Net profit | SEK -40,9M | +7% |
| Total assets | SEK 143,2M | +14% |
| Equity | SEK 134,6M | +13% |
| Employees | — | — |
Legal name
Iconovo AB
Org number
5569380156
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
24 juli 2013
Share capital
SEK 2 122 000
Employees
10-19
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Firman tecknas av en av ledamöterna i förening med Månsson, Lars John Anders Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Företaget ska bedriva verksamhet inom följande områden: Handel, utveckling och tillverkning av produkter samt konsulttjänster inom life science, där begreppet life science innefattar medicin-teknisk utrustning, farmaceutisk produktutveckling, verksamhet inom sjuk- och hälsovård, medicinteknisk produktutveckling, uppdragsforskning inom life science, utbildning inom life science, samt annan därmed förenlig verksamhet.
Address
Ideongatan 3 B
Email
info@iconovo.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 17 792 | 15 409 | 17 116 | 7 078 | 2 934 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −12 717 | −21 160 | −39 270 | −37 064 | −33 973 |
| Depreciation & amort. | −4 000 | −5 352 | −9 088 | −7 469 | −7 403 |
| EBIT | −16 717 | −26 512 | −48 358 | −44 533 | −41 376 |
| Net financials | −416 | 344 | 155 | 281 | 413 |
| Profit before tax | −17 134 | −26 161 | −48 163 | −44 202 | −40 938 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −17 134 | −26 161 | −48 163 | −44 202 | −40 938 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 101 045 | 148 544 | 121 266 | 125 557 | 143 188 |
| Equity | 95 729 | 137 035 | 89 294 | 118 748 | 134 635 |
| Long-term debt | 0 | 0 | 7 699 | 0 | 0 |
| Short-term debt | 8 315 | 11 509 | 24 273 | 6 810 | 8 552 |
| Total debt | 8 315 | 11 509 | 31 972 | 6 810 | 8 552 |
EBITDA margin
-1157.9%
This company
15.8%
Market median
-7428% vs market
20202024
Equity ratio
94.0%
This company
38.2%
Market median
+146% vs market
20202024
Return on equity
-30.4%
This company
18.4%
Market median
-265% vs market
20202024
Net profit margin
-1395.3%
This company
8.1%
Market median
-17326% vs market
20202024
Asset turnover
0.02×
This company
1.12×
Market median
-98% vs market
20202024
Debt / equity
0.06×
This company
0.62×
Market median
+90% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
LJ Chief Executive Officer | Chief Executive Officer | 2025 |
MS Chief Auditor | Chief Auditor | 2020 |
| Former (1) | ||
JT Chief Executive Officer | Chief Executive Officer | 2022 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (7) | ||
| Board of Directors | 2025 | |
| Board of Directors | 2025 | |
| Board of Directors | 2020 | |
| Board of Directors | 2020 | |
| Board of Directors | 2020 | |
| Board of Directors | 2025 | |
| Chairman | 2024 | |
| Former (8) | ||
| Board of Directors | 2023 – 2023 | |
| Board of Directors | 2020 – 2025 | |
| Chairman | 2022 – 2024 | |
| Board of Directors | 2020 – 2024 | |
| Board of Directors | 2024 – 2025 | |
| Board of Directors | 2023 – 2023 | |
| Board of Directors | 2023 – 2023 | |
| Board of Directors | 2023 – 2023 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Iconovo AB 
Iconovo Pharma ABBoard members of Iconovo AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lars John Anders Månsson | Chief Executive Officer | 0 companies |
| Maria Sofia Ekelund | Chief Auditor | 0 companies |
| Johan Thore Fredrik Wäborg | Chief Executive Officer | 0 companies |
| Björn Andreas Engström | Board of Directors | 0 companies |
| Lars Christer Fredrik Fåhraeus | Board of Directors | 0 companies |
| Leif Stig Hansen | Board of Directors | 0 companies |
| Agneta Helene Walhagen | Board of Directors | 0 companies |
| Orest Lastow | Board of Directors | 0 companies |
| Berndt David Lennart Axelsson | Board of Directors | 0 companies |
| Nils Gunnar Gårdemyr | Chairman | 0 companies |
| Ann Ulrika Gidner | Board of Directors | 0 companies |
| Erik Olof Ekman | Board of Directors | 0 companies |
| Eva Maria Bech | Board of Directors | 0 companies |
| Sven Georges Totté | Board of Directors | 0 companies |
| Mats Håkan Johansson | Board of Directors | 0 companies |
| Erik Nils Österberg Westerlund | Board of Directors | 0 companies |
| Carl Gunnar Olof Lindgren | Chairman | 0 companies |
| Carl Martin Olof Lindgren | Board of Directors | 0 companies |